Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 15;47(2):42-52.
doi: 10.64719/pb.4361.

Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety

Matthew T Morris  1 , Sandip P Tarpada  1
Affiliations

Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety

Matthew T Morris et al. Psychopharmacol Bull. .

Abstract

Objective: Summarize and synthesize the current literature regarding long-acting injectable paliperidone palmitate for the treatment of schizophrenia.

Methods: A literature search of PubMed, Embase, and Web of Science was conducted in February 2016, using the following search terms in varying permutations: schizophrenia; antipsychotic medication; long-acting injectable; paliperidone palmitate; 3-monthly injectable.

Results: Once-monthly injectable paliperidone palmitate (PDP) has demonstrated comparable efficacy as 1st-generation long-acting injectable antipsychotics (LAIAs) in reducing disease severity and re-hospitalizations in schizophrenic patients. However, PDP leads to significantly less extrapyramidal symptoms than these older medications indicating a superior safety profile. Compared to oral 2nd-generation antipsychotics, PDP has shown less incidence of disease relapse related to medication non-compliance, particularly in real world populations. It also showed a similar safety profile as oral 2nd-generation antipsychotics, but with greater incidence of mild injection-site pain. A novel 3-monthly formulation of PDP has shown similar safety and efficacy as once-monthly PDP compared to placebo.

Conclusions: Overall, both 1-month and 3-month formulations of PDP are safe and effective in the treatment of schizophrenia and schizoaffective disorder. They may be most effective in patients with prior failed treatment of oral antipsychotics or other LAIAs, in patients with a history of medication noncompliance, or in patients with an individual preference for less frequent dosing.

Keywords: antipsychotic medication; long-acting injectable antipsychotics; paliperidone palmitate; psychopharmacology; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

DIsclosures of Potential Conflicts of Interest On behalf of both authors, the corresponding author states that there are no conflicts of interest or sources of funding to declare.

References

    1. Hugdahl K, Løberg EM, Specht K et al. Auditory hallucinations in schizophrenia: the role of cognitive, brain structural and genetic disturbances in the left temporal lobe. Frontiers in Human neuroscience. 2008;28(1):6. - PMC - PubMed
    1. Regier DA, Narrow WE, Rae DS et al. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry. 1993;50(2):85–94. - PubMed
    1. Rössler W, Salize HJ, Van Os J et al. Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology. 2005;15(4):399–409. - PubMed
    1. Murray CJL, Lopez AD. Harvard University Press; Cambridge, MA: 1996. The Global Burden of Disease; p. 21.
    1. Dixon LB, Lehman AF, Levine J et al. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin. 1995;21(4):567. - PubMed

LinkOut - more resources